Martin Laclav

Risankizumab for Ulcerative Colitis

Edouard Louis, Stefan Schreiber, Remo Panaccione et al. · JAMA · 2024 · 110 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 83 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +15

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese, Remo Panaccione, Brian G. Feagan et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 70 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +6

Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma

Petr Bušek, Zdislava Vaníčková, Petr Hrabal et al. · Pancreatology · 2016 · 40 citations

Medicine, Biochemistry, Oncology +10

Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss

J Škrha, Petr Bušek, Jana Uhrová et al. · Pancreatology · 2016 · 32 citations

Medicine, Biochemistry, Endocrinology +17